Genetron Health and JD Health Launch Strategic Partnership to Build an Innovative Internet-Based Model for Full-Cycle Cancer Management
On May 20, 2021, Genetron Health, a leading domestic precision medicine company, and JD Health, China’s online healthcare platform, announced the comprehensive launch of their strategic partnership. The two parties will deeply integrate their respective strengths to jointly create an “internet-based innovative model for full-cycle cancer management.” This strategic collaboration marks another exploration by JD Health in the field of full-cycle cancer management, and also signifies that Genetron Health’s early screening product for liver cancer has embarked on an in-depth exploration of its fourth major commercialization pathway—the “Internet + Healthcare” platform—following its previous channels through health check-up institutions, government public welfare projects, and hospital markets.
Pictured: The signing ceremony for the strategic partnership between Genetron Health and JD Health was held in grand style. From left to right, the leaders and guests are:
Zhang Zhenlong, General Manager of the Medical Insurance and Healthcare Development Department at JD Health; Xiao Jianbo, General Manager of the Internet Healthcare Department at JD Health; Liu Mingyan, General Manager of Healthy Cities at JD Health; Wang Dongyuan, General Manager of the Smart Healthcare Department at JD Health; Wang Yufang, General Manager of the Consumer Healthcare Department at JD Health; Xin Lijun, Senior Vice President of JD.com and CEO of JD Health; Wang Sizhen, Co-founder and CEO of Genetron Health; Lei Li, Senior Vice President of Genetron Health; Xu Ce, Chief Financial Officer of Genetron Health; Teng Lin, Vice President of Genetron Health; Zhang Fengling, Vice President of Genetron Health; Fu Tianchen, Senior Director of Strategic Products in the Early Screening Business Unit at Genetron Health
The partnership is driven by a dual-engine model combining online and offline operations, focusing on six core areas: consumer healthcare, internet-based liver disease management, government-led medical consortiums, mutual sharing of screening population resources, industry and patient education, and the establishment of oncology center resources. The initial phase of collaboration will focus on liver cancer and lung cancer. Genetron Health leverages its liquid biopsy product for early liver cancer screening, HCCscreen.TM, Human 8-Gene Mutation Combined Detection Kit, in partnership with JD Health, covers cancer early screening, molecular subtyping, medication guidance, and drug resistance monitoring, providing more precise, efficient, and accessible full-cycle cancer management services to a broader user base.
Caption: Genetron Health and JD Health Officially Sign Strategic Cooperation Agreement
Based on this collaboration, HCCscreenTMJD Health will soon launch the “520 Love Together, Care for Your Liver” health education campaign and a “618” special event focused on early liver cancer screening, providing professional and comprehensive health education content and early cancer screening services to high-risk populations. Meanwhile, the Human 8-Gene Mutation Combined Detection Kit will be available through JD Health’s online hospital and offline pharmacies, further enhancing the complete pathway for patient diagnosis, treatment, and rehabilitation management.
As a global leader in precision oncology, Genetron Health focuses on cancer genomics research and applications, striving to transform cancer diagnosis and treatment by leveraging advanced molecular biology and big data analytics. JD Health, an internet-based healthcare company, is dedicated to helping people access affordable, convenient, high-quality medical health products and services.
Xin Lijun, Senior Vice President of JD.com and CEO of JD Healthstated, “Leveraging JD Health’s comprehensive medical supply chain and healthcare service capabilities and resources across all scenarios, we will collaborate with Genetron Health to explore the field of early liver cancer screening, provide users with more convenient access to services that shift treatment interventions earlier, and jointly increase the penetration rate of liver cancer screening services.”
Wang Sizhen, Co-founder and CEO of Genetron Healthstated: “This collaboration signifies a deep integration of ‘internet technology + genomics.’ We aim to leverage the respective strengths of both parties to achieve the integration, upgrading, and transformation from technology to application systems. By implementing an innovative whole-cycle cancer management model, we seek to effectively serve society and jointly advance the early realization of the ‘Healthy China 2030’ goals.”
Genetron Health (NASDAQ: GTH) is a global leader in precision oncology, specializing in the research and application of cancer genomics. The company is committed to transforming cancer diagnosis and treatment by leveraging advanced molecular biology and big data analytics. Genetron Health has established a comprehensive portfolio of products and services spanning the entire cancer care continuum—from early screening, diagnosis, and treatment recommendations to monitoring and prognosis management. Furthermore, the company actively collaborates with partners across the industry value chain to expand innovative applications and scenarios for molecular testing technologies.
JD Health (6618.HK) is a subsidiary group under JD.com, dedicated to healthcare and medical services. Guided by its strategic positioning as a “supply chain-centric, medically service-driven, digitally empowered health management platform covering users’ entire life cycles and all scenarios,” JD Health has established a comprehensive and integrated “Internet + Healthcare” ecosystem. Its products and services span the entire industrial chain of pharmaceutical and health physical goods, the full spectrum of medical processes, all health-related scenarios, and the complete user life cycle.
This press release contains forward-looking statements regarding Genetron Health’s future expectations, plans, and projections, including those related to HCCscreenTMStatements regarding commercialization prospects involve corresponding risks and uncertainties, which may cause actual results to differ from the expectations described in such forward-looking statements. These statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks, uncertainties, and numerous factors that could cause actual results to differ materially from those described in any forward-looking statement. Other statements containing words such as “anticipate,” “believe,” “expect,” “plan,” and similar expressions also constitute forward-looking descriptions. Further information regarding these and other risks and uncertainties is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release should not be regarded as representing the Company’s views at any time after the date of this announcement. Genetron Health expects that future events and developments will cause the Company’s assumptions and estimates to change; however, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Scan the QR code above or click the link below to learn more about product details and go directly to the purchase page~
https://pro.jd.com/mall/active/Qv26yLw5JQVBdcHGoLz7T279Sm8/index.html